The Patent Finder

Baxter Biotech Technology SARL

Also on record
Records under this name other than patents Baxter Biotech Technology SARL holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Baxter Biotech Technology SARL

PatentTitleStatus Expires Confidence
US 6,136,565Methods of reducing the levels of protoporphyrin IX in recombinant hemoglobin preparations
Term ended
Term ended Oct 18, 2019 · From the USPTO record
Term endedTerm ended Oct 18, 2019From the USPTO record
US 6,171,826Methods of controlling beta dimer formation in hemoglobin
Term ended
Term ended May 14, 2019 · From the USPTO record
Term endedTerm ended May 14, 2019From the USPTO record
US 6,242,417Stabilized compositions containing hemoglobin
Term ended
Term ended Jun 5, 2018 · From the USPTO record
Term endedTerm ended Jun 5, 2018From the USPTO record
US 6,160,098Method for control of functionality during cross-linking of hemoglobins
Term ended
Term ended May 29, 2018 · From the USPTO record
Term endedTerm ended May 29, 2018From the USPTO record
US 6,114,505Hemoglobin mutants that reduce heme loss
Formerly held
Term ended
Term ended Apr 22, 2018 · From the USPTO record
Term endedTerm ended Apr 22, 2018From the USPTO record
US 6,022,849Mutant recombinant hemoglobins containing heme pocket mutations
Term ended
Term ended Feb 8, 2017 · From the USPTO record
Term endedTerm ended Feb 8, 2017From the USPTO record
US 6,828,125DNA encoding fused di-alpha globins and use thereof
Lapsed on the fee record
Ended Dec 7, 2016 · From the USPTO record
Lapsed on the fee recordEnded Dec 7, 2016From the USPTO record
US 6,670,323Reduced side-effect hemoglobin compositions
Formerly held
Lapsed on the fee record
Ended Dec 30, 2015 · From the USPTO record
Lapsed on the fee recordEnded Dec 30, 2015From the USPTO record
US 6,455,676Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
Lapsed on the fee record
Ended Sep 24, 2014 · From the USPTO record
Lapsed on the fee recordEnded Sep 24, 2014From the USPTO record
US 7,049,406Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
Lapsed on the fee record
Ended May 23, 2014 · From the USPTO record
Lapsed on the fee recordEnded May 23, 2014From the USPTO record
10 of 44 patents shown.
Pro members see all 44.
Pro members: see all 44 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited